While reporting a net loss in mid-2025, it reaffirmed revenue growth guidance of 15–22%. : Trading around $8.05 as of April 2026.
Consistently featured in lists of best biotechs under $10 and is noted for its Cancer BioShield platform targeting lymphopenia.
AI responses may include mistakes. For financial advice, consult a professional. Learn more
Identified as a top pick for its focus on like Fabry and Pompe disease.
It maintains significant institutional interest, with roughly 31 hedge fund holders reported. :